Anti-PD-1 and PD-L1 antibodies, such as Nivolumab and Pembrolizumab, have displayed a manageable safety and promising efficacy to reduce tumor burden for patients with advanced gastric cancer (2, 3). Here, CD274 is linked to neoplasm.